3月12日,全球制药巨头礼来公司(Eli Lilly)发布了一项关乎无数使用者安全的公开警示:其明星降糖/减重药物替尔泊肽(Tirzepatide)在与维生素B12混合后,经检测发现了含量显著的未知杂质。 这一发现不仅让打着“个性化”旗号盛行的复合药物安全性受到严峻拷问,也凸显了监管灰色地带对患者构成的潜在危险。 礼来在声明中指出,公司对在美国市场销售、含替尔泊肽与B12(包括甲钴胺、羟钴胺或...
Source Link3月12日,全球制药巨头礼来公司(Eli Lilly)发布了一项关乎无数使用者安全的公开警示:其明星降糖/减重药物替尔泊肽(Tirzepatide)在与维生素B12混合后,经检测发现了含量显著的未知杂质。 这一发现不仅让打着“个性化”旗号盛行的复合药物安全性受到严峻拷问,也凸显了监管灰色地带对患者构成的潜在危险。 礼来在声明中指出,公司对在美国市场销售、含替尔泊肽与B12(包括甲钴胺、羟钴胺或...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.